Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | BTN3A1 | O00481 | 3/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.41 |
| ▸ | ENO1 | P06733 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439677 | 0.83 | LMNA (0.57) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9193616 | 0.81 | HTT (0.48) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL19014710 | 0.80 | LMNA (0.40) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9189677 | 0.80 | LMNA (0.44) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9193612 | 0.79 | HTT (0.46) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9189809 | 0.78 | HTT (0.46) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9189651 | 0.78 | HTT (0.46) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL9204222 | 0.77 | LMNA (0.53) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL13538361 | 0.76 | LMNA (0.58) | LMNASMN1; SMN2HTTL3MBTL1MAPT | |
| SCHEMBL21189481 | 0.76 | ALDH1A1 (0.49) | LMNAL3MBTL1BTN3A1ENO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2010019208-A1 | FLAVIN DERIVATIVES | BIORELIX PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | LMNA 3529/4885SMN1; SMN2 4259/4885HTT 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.